Skip to content

Personalis

US · PSNL #2890 by market cap Listed 2019
16.00 -0.03 -0.19%
Live - 5344 symbols - heartbeat 420s ago · 2026-10-08 04:13
Pre-market 16.07 +0.46%
After-hours 15.90 -0.63%
Market cap
1.71B
P/B
7.27
EPS
-0.91
Reader sentiment Are you bullish or bearish on PSNL?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 7.28 Expensive vs history 97th percentile
5-year average 1.94 · #28 of 40 in Diagnostics & Research
P/E ratio -14.71 Cheap vs history 5th percentile
5-year average -4.43 · forward -16.65
P/S ratio 24.57 Expensive vs history 97th percentile
5-year average 5.57 · forward 17.93 · #39 of 43 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Personalis (PSNL) 1.71B -14.68 7.27 0.00%
Thermo Fisher Scientific (TMO) 244.79B 35.63 4.65 0.27%
Danaher (DHR) 153.60B 38.81 2.92 0.66%
Natera (NTRA) 57.02B -293.01 31.30 0.00%
Agilent Technologies (A) 47.67B 33.35 6.47 0.60%
Waters (WAT) 42.84B 110.38 2.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value10.97 Economic moatNone UncertaintyExtreme

Trading 31.5% above Morningstar's fair value estimate.

Fair value

Personalis Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 46% premium over our quantitative fair value estimate of $10.97 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 13.6%, which falls in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 4.4%, for example, sits in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 04:13:33 · For reference only, not investment advice and not tailored to your situation.